Sangamo Therapeutics, Inc. (SGMO)
OTCMKTS · Delayed Price · Currency is USD
0.1851
+0.010785 (6.19%)
At close: May 26, 2026

Sangamo Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-123.33-122.93-97.94-257.83-192.28-178.29
Depreciation & Amortization
6.567.69.3622.1920.5617.64
Loss (Gain) From Sale of Assets
---1.03---
Asset Writedown & Restructuring Costs
13.2413.245.52155.01--
Loss (Gain) From Sale of Investments
----2.33-1.242.84
Stock-Based Compensation
7.489.0812.3827.3631.6532.96
Other Operating Activities
0.030.030.06-5.22--6.51
Change in Accounts Receivable
-0.510.160.42.762.34-0.79
Change in Accounts Payable
3.512.79-14.175.5913.35-7.66
Change in Unearned Revenue
-7.15-6.6613.43-161.16-91.33-84.2
Change in Income Taxes
--0.56-3.73--
Change in Other Net Operating Assets
5.32-0.524.29-7.49-6.67-9.24
Operating Cash Flow
-90.34-97.21-67.14-224.84-223.63-233.25
Capital Expenditures
-0.12-0.1-0.27-21.16-20.17-23.28
Sale of Property, Plant & Equipment
--1.95---
Cash Acquisitions
------0.12
Investment in Securities
--35.84174.6979.46271.6
Investing Cash Flow
-0.12-0.137.52153.5359.29248.2
Issuance of Common Stock
90.7374.0129.2816.0486.7636.12
Repurchase of Common Stock
-1.42-3.26-0.9-1.45-2.1-3.26
Financing Cash Flow
89.3170.7528.3814.5984.6632.86
Foreign Exchange Rate Adjustments
2.054.09-2.051.481.25-0.26
Net Cash Flow
0.91-22.47-3.29-55.24-78.4347.54
Free Cash Flow
-90.46-97.31-67.41-246-243.8-256.53
Free Cash Flow Margin
-261.76%-246.03%-116.62%-139.59%-219.05%-231.73%
Free Cash Flow Per Share
-0.28-0.35-0.33-1.41-1.58-1.77
Levered Free Cash Flow
-46.97-56.76-38.03-98.11-110.51-107.24
Unlevered Free Cash Flow
-46.97-56.76-38.03-98.11-110.51-107.24
Change in Working Capital
5.7-4.224.51-164.03-82.32-101.9
Source: S&P Global Market Intelligence. Standard template. Financial Sources.